Ashwani Verma
Stock Analyst at UBS
(2.21)
# 2,719
Out of 4,944 analysts
76
Total ratings
39.62%
Success rate
-0.72%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $32 → $36 | $25.45 | +41.45% | 5 | Aug 8, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $43 → $38 | $37.95 | +0.13% | 4 | Jul 30, 2025 | |
| IMVT Immunovant | Maintains: Neutral | $17 → $18 | $15.20 | +18.42% | 1 | Jul 28, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $152 → $174 | $128.89 | +35.00% | 9 | Jul 9, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $60 → $54 | $36.99 | +45.99% | 3 | Jul 2, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $410 → $385 | $301.39 | +27.74% | 5 | Jun 30, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $24 → $23 | $16.60 | +38.55% | 9 | Jun 26, 2025 | |
| ALKS Alkermes | Upgrades: Buy | $33 → $42 | $27.43 | +53.12% | 5 | Jun 17, 2025 | |
| INCY Incyte | Maintains: Neutral | $61 | $81.61 | -25.25% | 1 | Jun 3, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $47 → $41 | $34.31 | +19.50% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $48 | $35.47 | +35.33% | 2 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $0.92 | +14.64% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $179 | $113.33 | +57.95% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $14 | $13.40 | +4.48% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $72.50 | +57.24% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $13.47 | +300.89% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $105.23 | -0.22% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $35.86 | -21.92% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $116.56 | -93.99% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $10.12 | +18.58% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.53 | +2,724.86% | 1 | Oct 11, 2022 |
ACADIA Pharmaceuticals
Aug 8, 2025
Maintains: Buy
Price Target: $32 → $36
Current: $25.45
Upside: +41.45%
Exelixis
Jul 30, 2025
Maintains: Neutral
Price Target: $43 → $38
Current: $37.95
Upside: +0.13%
Immunovant
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $15.20
Upside: +18.42%
Neurocrine Biosciences
Jul 9, 2025
Maintains: Buy
Price Target: $152 → $174
Current: $128.89
Upside: +35.00%
Legend Biotech
Jul 2, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $36.99
Upside: +45.99%
United Therapeutics
Jun 30, 2025
Maintains: Buy
Price Target: $410 → $385
Current: $301.39
Upside: +27.74%
Teva Pharmaceutical Industries
Jun 26, 2025
Maintains: Buy
Price Target: $24 → $23
Current: $16.60
Upside: +38.55%
Alkermes
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $27.43
Upside: +53.12%
Incyte
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $81.61
Upside: -25.25%
Cytokinetics
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $34.31
Upside: +19.50%
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $35.47
Upside: +35.33%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $0.92
Upside: +14.64%
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $113.33
Upside: +57.95%
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $13.40
Upside: +4.48%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $72.50
Upside: +57.24%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $13.47
Upside: +300.89%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $105.23
Upside: -0.22%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $35.86
Upside: -21.92%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $116.56
Upside: -93.99%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $10.12
Upside: +18.58%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.53
Upside: +2,724.86%